OpGen (OPGN) Hits New 52-Week Low at $1.02

Shares of OpGen Inc (NASDAQ:OPGN) reached a new 52-week low during trading on Thursday . The stock traded as low as $1.02 and last traded at $1.05, with a volume of 623 shares traded. The stock had previously closed at $1.09.

OPGN has been the subject of several recent analyst reports. HC Wainwright set a $6.00 target price on shares of OpGen and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research cut shares of OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, November 7th.

The company has a market capitalization of $9.08 million, a P/E ratio of -0.11 and a beta of 1.92. The company has a current ratio of 1.56, a quick ratio of 1.43 and a debt-to-equity ratio of 0.28.

OpGen (NASDAQ:OPGN) last released its earnings results on Tuesday, November 13th. The medical research company reported ($0.53) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.02. The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.56 million. OpGen had a negative net margin of 395.63% and a negative return on equity of 238.35%. On average, research analysts forecast that OpGen Inc will post -2.19 earnings per share for the current year.

A hedge fund recently bought a new stake in OpGen stock. Acadian Asset Management LLC purchased a new stake in OpGen Inc (NASDAQ:OPGN) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 58,906 shares of the medical research company’s stock, valued at approximately $105,000. Acadian Asset Management LLC owned approximately 0.99% of OpGen as of its most recent SEC filing. Hedge funds and other institutional investors own 4.08% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/12/08/opgen-opgn-hits-new-52-week-low-at-1-02.html.


OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Further Reading: How to Track your Portfolio in Google Finance

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply